Telo Genomics Corp.

Recent News

  • Telo Genomics Appoints Kris Weinberg as Chief Executive Officer

    Toronto, Ontario--(Newsfile Corp. - December 12, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the appointment of Kris Weinberg as Chief Executive Officer ("CEO"), effective today. Telo Genomics' current CEO, Sherif Louis PhD, will assume the position of President & Chief Technology Officer. "These executive changes are integral to TELO's long term growth strategy," said John Meekison, Telo Genomics Board Director & Chair of the Audit Committee. "Sherif has spear-headed the...

    2022-12-12 8:45 AM EST
  • Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual Meeting

    Toronto, Ontario--(Newsfile Corp. - December 8, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the formation of a multiple myeloma advisory board ("MM Advisory Board"). Driven by the success of TELO's recent clinical studies, announced on September 14, 2022, and as part of the Company's commercialization strategy, the Company has prioritized the formation of an internationally recognized clinical advisory board to help guide the development and commercial launch of its predictive...

    2022-12-08 8:30 AM EST
  • Telo Genomics Launches a Minimal Residual Disease Clinical Trial in Multiple Myeloma

    Toronto, Ontario--(Newsfile Corp. - November 9, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce today that it is launching a clinical trial to monitor multiple myeloma disease progression in post-treated patients, by measuring and profiling the minimal residual disease ("MRD") in these patients. The clinical trial is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada. The trial is listed on the website of the...

    2022-11-09 8:30 AM EST
  • Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory Board

    Toronto, Ontario--(Newsfile Corp. - October 18, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma ("MM") clinician, key opinion leader and medical diagnostics expert to establish and chair TELO's MM clinical advisory board (the "Advisory Board").Driven by the progress of TELO's clinical studies announced on September 14, 2022, and as part of the Company's commercialization strategy, the...

    2022-10-18 8:30 AM EDT
  • Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

    Toronto, Ontario--(Newsfile Corp. - September 14, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma ("SMM"), in collaboration with the Mayo Clinic, has completed review and analysis of its first cohort, consisting of 187 patients and has exceeded its targeted endpoints.In July 2022, the Company announced that it had completed processing of the patient samples related to...

    2022-09-14 8:45 AM EDT
  • Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples

    Toronto, Ontario--(Newsfile Corp. - August 17, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces the completion of the laboratory processing and analysis of patient samples related to its multiple myeloma drug resistance clinical study. The patient samples were provided by the Mayo Clinic as part of an ongoing collaboration to evaluate the Company's prognostic technology for multiple myeloma ("MM"). TELO's study results have now been submitted back to the Mayo Clinic for review and...

    2022-08-17 8:45 AM EDT
  • Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma

    Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has commenced the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma ("MM") patients that are at high-risk of developing treatment resistance. This study is the second study being carried out in collaboration with the Mayo Clinic to evaluate the Company's prognostic technology to address multiple unmet clinical needs in MM.MM...

    2022-07-13 8:45 AM EDT
  • Telo Genomics Completes Processing and Analysis of Smoldering Multiple Myeloma Patient Samples

    Toronto, Ontario--(Newsfile Corp. - July 6, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces the completion of the laboratory processing and analysis component of its clinical study for TELO's lead prognostic test for smoldering multiple myeloma ("SMM"). The SMM patient samples were provided by the Mayo Clinic in Q1 2022 as part of an ongoing collaboration to evaluate the Company's prognostic technology for multiple myeloma ("MM"). TELO's study results have now been submitted back...

    2022-07-06 8:15 AM EDT